CREKA has a high affinity for fibronectin and its complexes and can direct UMFNPs to the metastatic margins, whereas fibronectin is a marker of epithelial-to-mesenchymal transition in the ECM of high-risk breast cancers (Fig. 9F). Here, FN1 is linked to breast cancer.